Does Medicare Cover Wegovy? Weight Loss, Heart, MASH (2026)

Does Medicare cover Wegovy? Yes, in two ways, and which one applies depends on why you take it. For weight loss, Medicare covers Wegovy only through the temporary Medicare GLP-1 Bridge, at $50 a month, through December 31, 2027. For heart disease or the liver disease MASH, your Part D or Medicare Advantage plan is allowed to cover Wegovy. The catch: a study published November 6, 2026 found that almost no Medicare plans actually do.

This guide sorts it out by diagnosis, because that is how Medicare decides.

Does Medicare cover Wegovy? The short answer by diagnosis

Two rules shape this table. First, federal law keeps Part D plans from covering drugs used only for weight loss. Second, a Part D plan can cover a drug for a "medically accepted" use, and Wegovy's other FDA-approved uses count.

Does Medicare cover Wegovy for weight loss?

Yes, but only through the GLP-1 Bridge. Medicare.gov says the Bridge covers Wegovy (injection or tablet), Foundayo and the Zepbound KwikPen for a $50 monthly copay. It started July 1, 2026, and your approval lasts through December 31, 2027.

You qualify if you have Medicare drug coverage, are 18 or older, and meet one of these when you start:

You cannot use the Bridge if you have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease. Medicare.gov says your Part D plan "might cover" a GLP-1 for those instead. The $50 also does not count toward your Part D deductible or yearly out-of-pocket limit. Our full Medicare GLP-1 Bridge guide walks through the prior authorization step by step.

Does Medicare cover Wegovy for heart disease?

It can, and this is the part most people miss. Wegovy's label includes lowering the risk of major heart events (heart death, heart attack or stroke) in adults with established heart disease and either obesity or overweight. In the SELECT trial (NEJM, 2023), Wegovy cut that risk by 20% compared with placebo. In March 2024, Medicare clarified that Part D plans could cover Wegovy for this use.

Some people did get it. A USC Schaeffer study in the American Journal of Managed Care (July 2026) found Medicare fills of Wegovy rose 598% after the heart approval. The same team estimated that about 3.6 million people on Medicare could be eligible, and only a small share got a prescription filled.

Our guide to GLP-1s and heart health explains the SELECT results in plain English. Heart failure is a separate question, since it is not on the Wegovy label; see Wegovy heart failure.

The new study: Medicare plans rarely cover Wegovy

On November 6, 2026, USC Schaeffer researchers Alice Chen and Eunhae Shin published a study in Health Affairs Scholar on Medicare plan formularies from 2024 to 2026. Here is what they found:

Most people who lost coverage lost it because their plan dropped GLP-1s from the formulary. Chen put it simply: these drugs are approved for serious conditions, "but the vast majority" of eligible people on Medicare still cannot get them covered.

What this means for you: if you have heart disease and a BMI under the Bridge cutoffs, check whether your heart condition already qualifies you for the Bridge (a past heart attack or stroke with a BMI of 27 or more does). That route may be easier than waiting for your plan.

Does Medicare cover Wegovy for MASH or fatty liver?

The Wegovy shot is FDA approved for adults with MASH and moderate to advanced liver scarring (F2 to F3) without cirrhosis. A Part D or Medicare Advantage plan may cover it for that use, usually with prior authorization and proof of the fibrosis stage. Because people with fatty liver disease are excluded from the Bridge, your plan is the only Medicare route here. See our Wegovy MASH guide for the criteria plans ask for.

Does Medicare cover Wegovy for sleep apnea or diabetes?

No, because Wegovy is not approved for either.

• Sleep apnea: Zepbound is the GLP-1 drug approved for moderate to severe obstructive sleep apnea in adults with obesity. A Part D plan may cover Zepbound for that use. Our Zepbound sleep apnea guide covers the details.
• Type 2 diabetes: Ozempic and Rybelsus contain the same drug as Wegovy and are approved for diabetes. Part D plans commonly cover them at the plan's copay.

Getting the most from Wegovy once Medicare covers it

Medicare asks your prescriber to confirm you are in a diet and exercise program for the Bridge. That matters more after 65. In the STEP 1 body scan substudy, roughly a third or more of the weight lost on semaglutide was lean mass, and older adults have less muscle to spare. Our guide to GLP-1s for seniors covers the extra safety points.

Two habits help the most: enough protein at each meal and regular strength work. Sharpy sets one daily protein target, gives you one 20-minute workout, and tracks a Shape Score so you can see whether you are losing fat or muscle.

What to do this month

1. Find your route. Use the diagnosis table above. Weight loss means the Bridge. Heart disease or MASH means your plan, or the Bridge if you also meet its BMI rules and are not excluded.
2. Pick your 2027 plan with care. Open enrollment runs through December 7, 2026. You need drug coverage to use the Bridge. If you want plan coverage for heart disease or MASH, check the plan's formulary for Wegovy before you enroll.
3. Know your cost cap. The Part D out-of-pocket limit is $2,100 in 2026 and rises to $2,400 in 2027. Bridge copays do not count toward it.
4. Ask your prescriber. Only they can decide if Wegovy is right for you and file the prior authorization. If you pay yourself instead, our Wegovy pill cost guide lists self-pay prices.

When you start, use Sharpy to keep the weight you lose coming from fat, not muscle.

Sources

• USC Schaeffer: Medicare Plans Rarely Cover Anti-Obesity Drugs for Other FDA-Approved Purposes (Nov 6 2026)
• Chen and Shin, Health Affairs Scholar (2026)
• USC Schaeffer: Medicare Prescriptions for Wegovy Jumped After Approval for Heart Disease (Jul 9 2026)
• Medicare.gov: Weight loss drugs (GLP-1 Bridge)
• Wegovy prescribing information (DailyMed)
• Lincoff et al. SELECT trial. NEJM 2023
• UnitedHealthcare: Medicare Part D changes (2027 out-of-pocket limit)